(Reuters) -The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients. Takeda's Adzynma becomes ...

Thanks to a Takeda approval Thursday, patients now have a drug to tackle a rare inherited blood clotting disorder. The U.S. FDA has given a green light to Takeda’s Adzynma, the first recombinant ...

A Takeda Pharmaceutical drug is now the first FDA-approved therapy for a rare, inherited enzyme deficiency that leads to blood clotting problems and a cascade of complications, some of them ...